BioCardia (BCDA) vs Passage Bio (PASG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
BioCardia (BCDA) has outperformed Passage Bio (PASG) over the past year, losing 25.4% versus a loss of 54.3%. Over five years, BCDA leads with a -97.6% price change compared with -98.1% for PASG. BioCardia is the larger company by market cap ($16.0 million vs $12.2 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCDA | PASG |
|---|---|---|
| Share price | $1.06 | $3.78 |
| Market cap | $16.05M | $12.16M |
| 1-day change | -2.75% | -1.95% |
| YTD return | -15.20% | -67.97% |
| 1-year return | -25.35% | -54.35% |
| 5-year return | -97.59% | -98.06% |
| EPS (TTM) | $-0.64 | $-11.55 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.80 | $20.00 |
| 52-week low | $0.75 | $3.29 |
| Distance from 52-week high | -41.11% | -81.10% |
| Analyst consensus | none | buy |
| Avg. price target upside | +1362.26% | +310.05% |
| Average volume | 282.05K | 26.11K |
| Shares outstanding | 15.14M | 3.22M |
| Employees | 17 | 24 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BCDA has outperformed PASG by 29.0 percentage points over the past year.
About BioCardia
BCDA stock →BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.
Healthcare · Biotechnology · 17 employees
About Passage Bio
PASG stock →Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease.
Healthcare · Biotechnology · 24 employees
BCDA vs PASG FAQ
Which is bigger, BioCardia or Passage Bio?
BioCardia (BCDA) is larger, with a market capitalization of $16.05M compared with $12.16M for Passage Bio (PASG).
Which stock has performed better over the past year, BCDA or PASG?
BCDA returned -25.35% over the past 12 months, compared with -54.35% for PASG (price return, excluding dividends). Past performance does not predict future results.
Are BioCardia and Passage Bio in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.